More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer

European Urology

Volumn 67, Issue 2, 2015, Pages 212-219

  Abdollah, Firas ^a   Gandaglia, Giorgio ^a   Suardi, Nazareno ^a   Capitanio, Umberto ^a   Salonia, Andrea ^a   Nini, Alessandro ^a   Moschini, Marco ^a   Sun, Maxine ^b   Karakiewicz, Pierre I ^b   Shariat, Sharhokh F ^c   Montorsi, Francesco ^a   Briganti, Alberto ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Lymph node dissection; Lymph node invasion; Neoplasm recurrence; Prostatic neoplasms mortality; Prostatic neoplasms pathology; Prostatic neoplasms surgery

Indexed keywords

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER SPECIFIC MORTALITY; CANCER STAGING; CANCER SURVIVAL; EXTENDED PELVIC LYMPH NODE DISSECTION; FOLLOW UP; GLEASON SCORE; HUMAN; LYMPH NODE INVASION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SURVIVAL RATE; TERTIARY CARE CENTER; TUMOR INVASION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVERSE EFFECTS; CANCER GRADING; CHI SQUARE DISTRIBUTION; ITALY; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RISK FACTOR; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84920683474     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.05.011     Document Type: Article

References (33)

1. B.L. Jacobs, Y. Zhang, and F.R. Schroeck Use of advanced treatment technologies among men at low risk of dying from prostate cancer JAMA 309 2013 2587 2595
2. F. Abdollah, M. Sun, and R. Thuret A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006 Eur Urol 59 2011 88 95
3. A. Heidenreich, P.J. Bastian, and J. Bellmunt EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent - update 2013 Eur Urol 65 2014 124 137
4. A. Briganti, F. Abdollah, and A. Nini Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection Eur Urol 61 2012 1132 1138
5. D.S. DiMarco, H. Zincke, T.J. Sebo, J. Slezak, E.J. Bergstralh, and M.L. Blute The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era J Urol 173 2005 1121 1125
6. J. Ji, H. Yuan, L. Wang, and J. Hou Is the impact of the extent of lymphadenectomy in radical prostatectomy related to the disease risk? A single center prospective study J Surg Res 178 2012 779 784
7. S.A. Joslyn, and B.R. Konety Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer Urology 68 2006 121 125
8. T.A. Masterson, F.J. Bianco, and A.J. Vickers The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer J Urol 175 2006 1320 1324 discussion 1324-5
9. A.M. Murphy, D.S. Berkman, M. Desai, M.C. Benson, J.M. McKiernan, and K.K. Badani The number of negative pelvic lymph nodes removed does not affect the risk of biochemical failure after radical prostatectomy BJU Int 105 2010 176 179
10. R. Schiavina, F. Manferrari, and M. Garofalo The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer BJU Int 108 2011 1262 1268
11. T.J. Bivalacqua, P.M. Pierorazio, M.A. Gorin, M.E. Allaf, H.B. Carter, and P.C. Walsh Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy Urology 82 2013 653 658
12. K.A. Touijer, C.R. Mazzola, D.D. Sjoberg, P.T. Scardino, and J.A. Eastham Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy Eur Urol 65 2014 20 25
13. P.M. Pierorazio, M.A. Gorin, and A.E. Ross Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience Prostate 73 2013 1673 1680
14. C. Cozzarini, F. Montorsi, and C. Fiorino Need for high radiation dose (≥70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients Int J Radiat Oncol Biol Phys 75 2009 966 974
15. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974
16. Harrell FE. rms: regression modeling strategies (2012). R package v.3.5-0. http://CRAN.R-project.org/package=rms.
17. G. Gandaglia, Q.D. Trinh, and J.C. Hu The impact of robot-Assisted radical prostatectomy on the use and extent of pelvic lymph node dissection in the "post-dissemination" period Eur J Surg Oncol 40 2014 1080 1086
18. T.J. Wilt, M.K. Brawer, and K.M. Jones Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 2012 203 213
19. A. Vickers, C. Bennette, and G. Steineck Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial Eur Urol 62 2012 204 209
20. G. Ploussard, A. Briganti, and A. de la Taille Pelvic lymph node dissection during robot-Assisted radical prostatectomy: efficacy, limitations, and complications-A systematic review of the literature Eur Urol 65 2014 7 16
21. F. Abdollah, N. Suardi, and A. Gallina Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center Ann Oncol 24 2013 1459 1466
22. A. Heidenreich, Z. Varga, and R. Von Knobloch Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis J Urol 167 2002 1681 1686
23. S. Joniau, L. Van den Bergh, and E. Lerut Mapping of pelvic lymph node metastases in prostate cancer Eur Urol 63 2013 450 458
24. F. Abdollah, N. Suardi, and C. Cozzarini Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis Eur Urol 63 2013 998 1008
25. A. Briganti, R.J. Karnes, and L.F. Da Pozzo Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis Eur Urol 59 2011 832 840
26. L.F. Da Pozzo, C. Cozzarini, and A. Briganti Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy Eur Urol 55 2009 1003 1011
27. A. Briganti, J.R. Karnes, and L.F. Da Pozzo Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy Eur Urol 55 2009 261 270
28. A. Briganti, U. Capitanio, and F.K.-H. Chun Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer Eur Urol 54 2008 794 804
29. C. Mazzola, C. Savage, and Y. Ahallal Nodal counts during pelvic lymph node dissection for prostate cancer: an objective indicator of quality under the influence of very subjective factors BJU Int 109 2012 1323 1328
30. C.G. Eden, E. Zacharakis, and S. Bott The learning curve for laparoscopic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer: implications for compliance with existing guidelines BJU Int 112 2013 346 354
31. D. Sagalovich, A. Calaway, A. Srivastava, P. Sooriakumaran, and A.K. Tewari Assessment of required nodal yield in a high risk cohort undergoing extended pelvic lymphadenectomy in robotic-Assisted radical prostatectomy and its impact on functional outcomes BJU Int 111 2013 85 94
32. R. Seiler, U.E. Studer, K. Tschan, P. Bader, and F.C. Burkhard Removal of limited nodal disease in patients undergoing radical prostatectomy: long-term results confirm a chance for cure J Urol 191 2014 1280 1285
33. A. Briganti, A. Larcher, and F. Abdollah Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores Eur Urol 61 2012 480 487